
    
      A 48 Week, Phase II, non-comparative, open-label, multi-cohort, multicenter study to evaluate
      the safety, tolerability, pharmacokinetics and antiviral activity of GW433908/Ritonavir BID
      when administered to HIV-1 infected PI-Naive and experienced, Pediatric Subjects 2 to 18
      years old and of GW433908 BID Administered to PI-Naive Pediatric subjects 2 to <6 years old
    
  